semaglutide cause seizures Association Between GLP-1 Receptor Agonist Use and Epilepsy Risk in Type 2 Diabetes Neuroprotective effects of glucagon-like peptide-1

Anyone unwilling to consult a licensed provider

Chronic high-dose agonism and GLP-1 receptor downregulation: what do we know

For those impurities that are present at acceptable levels, an in silico risk assessment can identify immunogenic risk at an early stage in the development process, enabling the removal of higher risk impurities while also indicating additional in vitro assays (HLA binding and T cell assay) that would be most useful in further evaluating immunogenicity

Preclinical and early clinical trials reveal that these dual-acting peptides can deliver multiple pharmacological effects, including enhanced glucose regulation and significant weight reduction

Both are effective when used consistently